Background: Progerin is a mutant form of lamin A responsible for Hutchinson-Gilford progeria
Introduction
Hutchinson-Gilford progeria syndrome (HGPS) is an extremely rare sporadic genetic disorder that is characterized by accelerated cardiovascular disease and premature aging.
1, 2 Most (>90%) HGPS patients carry a non-inherited autosomal dominant de novo heterozygous mutation at codon 608 of the LMNA gene (c.1824C>T: GGC>GGT; p.G608G). This mutation activates a cryptic splice donor site, causing the synthesis of progerin. 1, 2 Expression of this lamin A mutant disrupts the nuclear membrane architecture and causes multiple cellular alterations, including impaired DNA repair capacity and abnormal higher-order chromatin organization, gene transcription and signal transduction. 3, 4 HGPS patients exhibit accelerated atherosclerosis and die at a mean age of 13.4 years (range, 8-21 years) predominantly from myocardial infarction or stroke. [5] [6] [7] Additional clinical HGPS manifestations include dermal and bone abnormalities, alopecia and joint contractures. 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] Moreover, the aortas and aortic valves of HGPS patients are excessively calcified, [10] [11] [12] and arteries from old transgenic mice carrying a human bacterial artificial chromosome that harbors the common HGPS mutation accumulate calcium deposits that are absent in age-matched controls. 17 However, the mechanisms underlying excessive vascular calcification in HGPS remain unexplored.
Vascular calcification typically manifests as calcium-phosphate deposition (CPD) in distinct layers of the aortic wall. 18, 19 Calcium-phosphate deposits are composed of several members of the calcium orthophosphate family, including hydroxyapatite, octocalcium phosphate and amorphous calcium phosphate. 20 Medial calcification occurs within the elastin region of arteries and is almost exclusively associated with vascular smooth muscle cells (VSMCs). Elevated serum phosphorus (in the form of inorganic phosphate) is a major risk factor for vascular calcification. 21, 22 In vitro and in vivo studies have shown that elevated inorganic phosphate concentration in VSMCs triggers a transition to a bone-forming phenotype. 18, 19 This transition results in over-expression of osteochondrogenic markers, such as the transcription factor Runx2 (also named Cbfa1), which induces the expression of major bone matrix components. 18, 19 Extracellular pyrophosphate (ePPi) directly blocks CPD in vitro and in vivo and is therefore a major endogenous inhibitor of vascular calcification. [23] [24] [25] [26] Degradation of ePPi is catalyzed by tissuenonspecific alkaline phosphatase (TNAP), which hydrolyzes PPi to inorganic phosphate. Importantly, calcification in ex vivo cultured rat aorta is induced by alkaline phosphatase and is prevented by TNAP inhibitors. 26, 27 TNAP is moreover up-regulated in the aortas of uremic rats, resulting in increased hydrolysis of ePPi and vascular calcification. 28 The main enzyme involved in ePPi synthesis, both in aorta and in cultured VSMCs, is the ectoenzyme nucleotide pyrophosphatase/phosphodiesterase-1 (eNPP1). 26, 29 Lack of eNPP1 leads to extensive and fatal arterial calcification in children and mice. 30, 31 The substrate for eNPP1 is ATP, which accumulates in the extracellular matrix via the action of several transporters, 32 such as the multiple-pass transmembrane protein ANK. 33 To define the molecular mechanisms that lead to vascular calcification in HGPS, we analyzed Lmna G609G knock-in mice, which express progerin as a consequence of aberrant splicing resulting from the LMNA c.1827C>T (p.G609G) mutation, equivalent to the human mutation c.1824C>T
(p.G608G). 34 This new mouse model of progeria mimics the main clinical manifestations of human HGPS, including cardiovascular aberrations and premature death. 34 Our studies reveal profound alterations in ePPi homeostasis caused by progerin expression that exacerbate vascular calcification, which is inhibited by pyrophosphate treatment. Cell culture. VSMCs were prepared from thoracic aortas of 30-32-week-old mice as described previously. 35 Cells were grown in minimal essential medium (MEM) containing 1 mM L-glutamine, 100 IU/ml penicillin, 100 µg/ml streptomycin and 10% fetal bovine serum (FBS) at 37ºC in a humidified atmosphere at 5% CO2. VSMCs were used at passages 5-10. Cells were grown to confluence and used after an overnight quiescence step (0.1% FBS). Calcification assays were performed on cells incubated for 7 days in MEM supplemented with 0.1% FBS and 2 mmol/L Pi as described previously. 35, 36 For phosphatase activity studies and ATP and PPi measurements, VSMCs were incubated in medium without Phenol Red.
METHODS

Mice
Quantification of calcium deposition. Aortic arch and thoracic aorta from wild-type and Lmna G609G/+ mice (n=5 per genotype) were included in OCT (Sakura, Netherlands), and 4-µm crosssections were cut with a cryostat (Leica CM1950, Barcelona, Spain). Calcification in aortic tissue was revealed by Alizarin red staining as described. 35, 36 To quantify calcium deposits, 2-4 aortic cross-sections of each mouse were analyzed with ImageJ (http://imagej.nih.gov/ij/docs/guide).
To quantify calcium content in VSMCs, cells were treated with 0.6 HCl overnight at 4ºC and analyzed with a colorimetric QuantiChrom calcium assay kit (BioAssay Systems, Hayward, California).
Pyrophosphate treatment in vivo. PPi (Sigma, S6422) was dissolved in sterile saline (B.Braun
Medical SA, Barcelona, Spain). 10-week-old Lmna G609G/G609G mice were treated with PPi for 9 weeks (daily intraperitoneal injection, 100 mg/Kg/day) and the control group received saline (n=5 mice in each group). Quantification of aortic calcification was performed as indicated above.
Quantitative real-time PCR (qPCR).
Total RNA was isolated from mouse aorta or VSMCs using Qiazol lysis reagent (Qiagen, Madrid, Spain). After DNase treatament, 2 µg RNA was reverse transcribed using the High capacity cDNA reverse transcription kit (Applied Biosystems, Madrid, Spain). qPCR was performed using Power SYBR Green in 384 Immunoblots and inmunohistochemistry. VSMC lysates were prepared in lysis buffer (0.1% SDS, 25 mM Tris-HCl pH 7.4 and protease inhibitors) and 30-50 µg protein were separated by SDS-PAGE and blotted to PVDF membrane as previously described. 35 The following primary antibodies were used: rabbit monoclonal anti-eNTPD1 (1/5000, ab108248, Abcam, Cambridge, UK), rabbit polyclonal anti-TNAP (1µg/ml, ab65834, Abcam), rabbit polyclonal anti-GFP (1/2500, ab6556, Abcam) and mouse monoclonal anti-α-Tubulin (1/5000, sc-8035, Santa Cruz biotechnology, USA).
After incubation with appropriate secondary antibodies, blots were revealed using the ECL system (Millipore, Billerica, MA, USA). Mouse aortas were immunohistochemically stained with a rabbit polyclonal antibody to Runx2 (1/500, ab102711, Abcam).
Phosphatase activity and ATP hydrolysis assays. Phosphatase activity in VSMCs or plasma was measured using the pNPP phosphatase assay kit and the Quantichrom alkaline phosphatase assay kit (BioAssay Systems), respectively. ATP hydrolysis assays in VSMCs cultures were performed as previously described. 26 Briefly, cells were seeded in 12-well plates and incubated for the indicated times with 1µM ATP and 1 μCi/mL [γ 32 P]ATP radiotracer (Perkin Elmer, Madrid, Spain). ATP, inorganic phosphate and PPi in the culture medium were then separated by chromatography on PEIcellulose plates and were developed with 650 mM KH2PO4 pH 3. After autoradiography, spots were excised and counted by liquid scintillation.
ATP and pyrophosphate quantification. ePPi was measured using an enzyme-linked bioluminescence assay in which PPi reacts with adenosine 5'-phosphosulfate (A5508, Sigma) in the presence of ATP-sulfurylase (A8957, Sigma) to generate ATP 29 . For each sample, the blank (reaction without ATP-sulfurylase) was subtracted to obtain the true PPi amount. ATP was measured by a coupled luciferin/luciferase reaction using an ATP determination kit (Invitrogen, Paisley, UK).
Generation of retroviral vectors and stable cell lines.
Wild-type pre-lamin A and progerin cDNAs were PCR amplified using as template a previously published construct 37 and 5A, results were analyzed using unpaired Student's t-test with Welch's correction for two samples with possibly unequal variance. The results in Figure 5B were analyzed using paired Student's t-test. In all cases, statistical significance was assigned at p<0.05. Runx2, two osteogenic markers expressed during vascular calcification, but no changes were observed in the anti-calcification agents matrix Gla-protein (MGP) and fetuin A (Fig.1B,C) .
RESULTS
Vascular smooth muscle calcification is increased in progeroid
Immunohistochemical analysis confirmed the increase in Runx2 expression in Lmna G609G/+ aortas compared with aortas from wild-type mice (Fig.1D ).
We next studied primary cultures of VSMCs isolated from aortic tissue of wild-type and Lmna G609G/+ mice. Previous in vitro studies showed that CPD is more prominent with lysed VSMCs than with live cells, suggesting that VSMCs synthesize CPD inhibitors. 25, 35, 36 We therefore compared the CPD-inhibitory capacity of wild-type and Lmna G609G/+ VSMCs. Cells were incubated for 7 days in calcifying medium, and the difference in CPD between lysed and live cells (ΔCa 2+ ) was calculated. Lmna G609G/+ VSMCs showed a significantly lower capacity to inhibit calcium deposition than equivalent numbers of control cells, after normalization for protein concentration (Fig 1E) .
Lmna G609G/+ VSMCs have an impaired capacity to synthesize extracellular pyrophosphate.
Since excessive calcification in Lmna G609G/+ aorta was not associated with reduced expression of MGP and fetuin A (Fig.1B) , we quantified in VSMC-conditioned culture medium the accumulation of ePPi, the major endogenous inhibitor of vascular calcification. 21, [23] [24] [25] [26] After 2 days in culture, ePPi levels were 3.8-fold lower in Lmna G609G/+ VSMCs compared with wild-type controls ( Fig.2A) . RT-PCR analysis of enzymes and transporters involved in ePPi metabolism demonstrated significantly higher expression of TNAP, Apyrase1/eNTPD1 and the phosphate transporter Pit2 in Lmna G609G/+ compared with wild-type VSMCs, whereas eNPP1, ANK and Pit1 were unaffected (Fig.2B) . Western blot analysis confirmed the increase in the ectoenzymes TNAP and eNTPD1 in Lmna G609G/+ VSMCs (Fig.2C) . Moreover, phosphatase activity was 2-fold higher in Lmna G609G/+ VSMCs (Fig.2D) .
Given these findings, we next investigated the capacity of Lmna G609G/+ VSMCs to synthesize (Fig.2E) . Accordingly, the Pi:PPi ratio increased from 1:1 in wild-type VSMCs to 2.4:1 in Lmna G609G/+ VSMCs.
VSMCs expressing progerin have impaired ATP synthesis and mitochondrial function.
Extracellular ATP hydrolysis is the major source of ePPi in aorta and in VSMCs. 26 We therefore analyzed intracellular ATP levels and extracellular ATP accumulation in wild-type and Lmna
G609G/+
VSMCs. Lmna G609G/+ VSMCs showed significantly lower levels of extracellular ATP (Fig.3A ) and intracellular ATP (Fig.3B) . Lmna G609G/+ VSMCs also exhibited lower mitochondrial ATP production (Fig.3C) . This was associated with a significantly lower COX/CS ratio (Fig.3D) , indicating impaired activity of COX, an essential component of the mitochondrial electron transport chain.
To assess whether the alterations observed in Lmna G609G/+ VSMCs are a direct consequence of progerin expression, we performed retrovirus-mediated gain-of-function experiments. Western blot analysis demonstrated CFP-lamin A and progerin-CFP expression in primary mouse VSMCs infected with retrovirus encoding these proteins (Fig.4A ). In agreement with many previous studies in different cell types, infected VSMCs expressed CFP-lamin A predominantly in the perinuclear rim, whereas progerin-CFP was found in both the perinuclear rim and in nucleoplasmic aggregates (Fig.4B) . Compared with VSMCs expressing CFP-lamin A, forced progerin expression in VSMCs led to increased TNAP and Apyrase1/eNTPD1 mRNA steady-state levels without affecting the expression of others enzymes and transporters involved in ePPi metabolism (Fig.4C) . Western blot analysis confirmed the increase in TNAP and eNTPD1 in Lmna G609G/+ VSMCs overexpressing progerin (Fig.4D) . Consistent with the results in primary Lmna G609G/+ VSMCs, we also found significant reductions in extracellular and intracellular ATP concentration, mitochondrial ATP synthesis, COX/CS ratio, and ePPi levels in progerin-CFP-overexpressing VSMCs compared with CFP-lamin A-expressing controls (Fig.4E ). or PPi over 9 weeks (100 mgkg -1 day -1 , n=5 mice in each group). We did not observe differences in body weight and mortality during follow-up, but post-mortem analysis demonstrated a statisticallysignificant reduction in aortic calcification in PPi-treated mice compared with controls, as revealed by planimetric analysis of Alizarin Red-stained aortic cross-sections (Fig.5B) .
DISCUSSION
The aim of the present study was to identify molecular mechanisms that contribute to excessive vascular calcification in HGPS, a rare premature aging disorder caused by abnormal expression of progerin. 1, 2 Available evidence indicates that vascular calcification involves both passive and active processes 18, 19, 25 (Fig.6) . CPD in the aortic wall and in in vitro models is the main feature of vascular calcification. At physiological serum concentrations of calcium and phosphate, CPD is a passive process that does not require cellular activity. 20, 25, 36, 40 Active processes involved in vascular calcification include reduced capacity of VSMCs to synthesize and secrete calcification inhibitors, such as MGP, fetuin A and ePPi, and the transition of VSMCs to a bone-forming phenotype, a process that is enhanced via CDP-dependent overexpression of osteochondrogenic factors, including Runx2. 18, 19, 36, 41 Pi is essential for the synthesis of ATP, the main source of ePPi. 26 It has thus been proposed that defective ATP production by VSMCs may impair the synthesis of CPD inhibitors. 42 Previous studies revealed that old transgenic mice carrying the common HGPS mutation exhibit a vascular calcification not seen in age-matched controls. 17 However, the mechanisms by which progerin exhacerbates vascular calcification remain unknown. Here, we have shown that progerin expression in Lmna G609G/+ mice causes excessive vascular calcification associated with VSMC abnormalities that lead to impaired mitochondrial function and ATP production and reduced PPi synthesis (Fig.6) , without affecting expression of the anti-calcification agents MGP and fetuin A. The causal relationship between progerin-induced low plasma ePPi and vascular calcification is reinforced by our observation that aortic calcification in progeroid mice is reduced by treatment with PPi. It is noteworthy that physiological aging of non-HGPS individuals is associated with mitochondrial dysfunction 43, 44 and with a progressive accumulation of progerin in several tissues, [45] [46] [47] [48] including vascular tissue. 6 Thus our findings might be relevant to vascular calcification not only in HGPS patients but also in the elderly.
Because HGPS patients carry the LMNA mutation in heterozygosis, 1, 2 we studied heterozygous Lmna G609G/+ mice that express both lamin A and progerin. 34 We found excessive aortic calcification in progeroid Lmna G609G/+ mice, which was associated with increased aortic expression of Runx2 and (Fig. 2E) . The defect in ePPi production by progerin-expressing VSMCs is unlikely to be counterbalanced systemically, because
PPi concentration in plasma from Lmna G609G/+ mice was also significantly reduced compared with wild-type controls, probably as a result of lower ATP concentration and higher alkaline phosphatase activity in plasma. Our observation that PPi treatment inhibits aortic calcification in progeroid mice underscores the role of defective ePPi homeostasis as a key factor underlying excessive vascular calcification in HGPS. We did not observe changes in body weight or mortality upon PPi treatment.
However, it is important to note that these studies were performed in homozygous Lmna G609G/G609G mice that have an average life span of only 15 weeks, 34 and treatment was started at 10 weeks of age, when the animals already exhibit severe symptoms. 34 HGPS patients carry the LMNA mutation in heterozygosis, 1, 2 and therefore future studies are warranted in very young heterozygous Lmna G609G/+ mice (1-2-weeks-old) to ascertain whether chronic treatment with PPi starting early in life, when symptoms are absent or very mild, can not only inhibit vascular calcification but also improve the general health and lifespan of progeroid mice.
Since imbalances in the degradation and synthesis of ePPi have been shown to lead to pathologic calcification of articular cartilage, 49 the systemic defect in circulating PPi associated with progerin expression might promote not only excessive vascular calcification but also the appearance of joint contractures, a characteristic of both HGPS patients 5 and Lmna G609G mice. 34 Treatment with
PPi might thus ameliorate both vascular calcification and joint contractures. It is noteworthy that combined treatment with statins and bisphosphonates (nonhydrolyzable pyrophosphate analogues)
significantly extends the average lifespan of progeroid Zmpste24 -/-mice, another model of premature aging caused by abnormal accumulation of prelamin A. 50 Based on these findings, ongoing clinical trials are assessing the efficacy of statin plus bisphosphonate (pravastatin plus zoledronate) with or without farnesyl transferase inhibitor (http://www.progeriaresearch.org/clinical_trial.html). However, although treatment with bisphosphonates decreases aortic calcification, animal studies have identified adverse effects of these compounds in bone. 51, 52 Moreover, bisphosphonates have been shown to induce the rupture of atherosclerotic plaques in apolipoprotein E-null mice. 53 In contrast, recent studies have shown that exogenous PPi injected daily into uremic rats and mice reduces the calcium content in calcified aortas without producing adverse effects on bone. 24, 39 Moreover, TNAP and PHOSPHO1 inhibitors can inhibit vascular calcification. 27, 54 Future studies in HGPS mouse models are thus warranted to investigate whether treatment with PPi in combination with TNAP or PHOSPHO1 inhibitors and FTI and statins is more beneficial than current strategies.
CLINICAL PERSPECTIVE
Progerin, a mutant form of lamin A, is responsible for Hutchinson-Gilford progeria syndrome (HGPS), a rare premature aging disorder featuring excessive vascular calcification (VC). Calcium dysfunction is under-studied in HGPS. Here, we show that progerin-expressing heterozygous 
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